The Cooper Companies, Inc.
At today's price, The Cooper Companies, Inc. (COO) is priced for +24.9% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
- Cooper is two durable medical franchises in one: CooperVision in contact lenses and CooperSurgical in fertility and women's health. The contact-lens business is the engine, and the standout line is MiSight, the myopia-control lens for children, which grew 23% in the latest quarter. - At $65.91 only the forward-growth methods reach the price. The asset, earnings-power, and peer-multiple lenses all land well below it, so the market is paying for durable compounding that the static frames cannot
Is COO overvalued? See what's priced in →
654 institutional managers reported holding COO in 13F filings for the quarter ended 2026-03-31. 90 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 7.3M shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (1.7 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
COO has cut its share count 1.1% over the past five years, spending $476.60M on repurchases. It pays no dividend. Cash returned over the past three years: $398.10M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at COO over the trailing three years: 2025: 10 buys totaling $2.52M. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
COO's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-06-03 | -4.0% | +9.1% |
| 2023-09-01 | -2.1% | -8.2% |
| 2023-12-09 | -2.2% | +12.4% |
| 2024-03-02 | +8.1% | -11.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
COO's latest 8-K filings: 2026-06-04 (items 2.02, 8.01, 9.01); 2026-05-04 (items 5.02); 2026-04-08 (items 5.07); 2026-03-05 (items 2.02, 9.01); 2026-02-04 (items 1.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.